Table 2.
Echocardiographic Measures and Study Outcomes for HIV-Infected Participants and Controls
| HIV+ (N = 332) | Control (N = 50) | P-value | |
|---|---|---|---|
| Ejection Fraction (%) | 61.0 (56.5–66.0) | 61.5 (59.0–67.0) | 0.35 |
| Systolic Dysfunction | 14 (5%) | 0 | 0.23 |
| Diastolic Dysfunction | 138 (45%) | 14 (28%) | 0.02 |
| Stage 1 | 128 (93%) | 14 (100%) | 0.60 |
| LV Mass Index (gm/m2) | 77.3 (66.2–88.7) | 66.4 (63.0–72.6) | <0.001 |
| Pulmonary Hypertension | 89 (27%) | 1 (2.0%) | <0.001 |
| PASP (mmHg) | 31.0 (25.0–36.0) | 22.5 (19.0–25.0) | <0.001 |
| Mortality Rate* | 10.3% (7.4%–14.2%) | 4.0% (1.3%–12.3%) | 0.094 |
Data are presented as Median (IQR) or numbers (percent).
*
Mortality is reported as five-year rate (95% CI)
Abbreviations: LV, left ventricular; PASP, pulmonary artery systolic pressure; IQR, interquartile range